Compare DexCom, Inc. (DXCM) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

TSLY, the YieldMax TSLA Option Income Strategy ETF, trades at $26.26, down 2.12% on the day. The technical picture is bearish with moving averages signaling strong selling pressure, though the short-term RSI suggests potential oversold conditions. The fund's primary focus is generating high income through synthetic TSLA exposure and covered call strategies, with recent weekly distributions averaging around $0.30 per share. Recent news highlights consistent weekly dividend announcements from YieldMax, maintaining the fund's high-yield distribution schedule.

The outlook centers on TSLY's ability to sustain its high-yield distributions through its options strategy, though this comes with capped upside potential and significant volatility risk tied to TSLA's price movements. Key risks include the fund's reliance on return of capital distributions, exposure to TSLA's stock volatility, and the complex options strategy that may underperform in certain market conditions. Investors should weigh the high income potential against the structural limitations and underlying asset risks.